Literature DB >> 773721

Glucose tolerance and insulin release, a mathematical approach I. Assay of the beta-cell response after oral glucose loading.

W J Sluiter, D W Erkelens, W D Reitsma, H Doorenbos.   

Abstract

From the dose-response relations between glucose and insulin after oral glucose loading, a reproducible parameter for beta-cell response was deduced. The main advantage of this parameter -corrected insulin response, defined as CIR = I- 100/G(G-70)- lies in it independence from the initial or reached glucose level.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 773721     DOI： 10.2337/diab.25.4.241

Source DB:  PubMed          Journal:  Diabetes        ISSN： 0012-1797            Impact factor:   9.461


  44 in total

1.  Common type 2 diabetes risk variant in MTNR1B worsens the deleterious effect of melatonin on glucose tolerance in humans.

Authors:  Marta Garaulet; Purificación Gómez-Abellán; Patricia Rubio-Sastre; Juan A Madrid; Richa Saxena; Frank A J L Scheer
Journal:  Metabolism       Date:  2015-08-14       Impact factor: 8.694

2.  A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion.

Authors:  R H Lustig; F Greenway; P Velasquez-Mieyer; D Heimburger; D Schumacher; D Smith; W Smith; N Soler; G Warsi; W Berg; J Maloney; J Benedetto; W Zhu; J Hohneker
Journal:  Int J Obes (Lond)       Date:  2006-02       Impact factor: 5.095

Review 3.  Pediatric endocrine disorders of energy balance.

Authors:  Robert H Lustig
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

4.  The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program.

Authors: 
Journal:  Diabet Med       Date:  2007-02       Impact factor: 4.359

5.  Prediabetes in Pediatric Recipients of Liver Transplant: Mechanism and Risk Factors.

Authors:  Emily R Perito; Robert H Lustig; Philip Rosenthal
Journal:  J Pediatr       Date:  2016-12-29       Impact factor: 4.406

6.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Authors:  N Matikainen; S Mänttäri; A Schweizer; A Ulvestad; D Mills; B E Dunning; J E Foley; M-R Taskinen
Journal:  Diabetologia       Date:  2006-07-01       Impact factor: 10.122

7.  Genetic and phenotypic correlations between surrogate measures of insulin release obtained from OGTT data.

Authors:  Anette P Gjesing; Rasmus Ribel-Madsen; Marie N Harder; Hans Eiberg; Niels Grarup; Torben Jørgensen; Claus T Ekstrøm; Oluf Pedersen; Torben Hansen
Journal:  Diabetologia       Date:  2015-02-09       Impact factor: 10.122

8.  Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.

Authors:  Abbas E Kitabchi; Marinella Temprosa; William C Knowler; Steven E Kahn; Sarah E Fowler; Steven M Haffner; Reuben Andres; Christopher Saudek; Sharon L Edelstein; Richard Arakaki; Mary Beth Murphy; Harry Shamoon
Journal:  Diabetes       Date:  2005-08       Impact factor: 9.461

9.  Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program.

Authors:  William C Knowler; Richard F Hamman; Sharon L Edelstein; Elizabeth Barrett-Connor; David A Ehrmann; Elizabeth A Walker; Sarah E Fowler; David M Nathan; Steven E Kahn
Journal:  Diabetes       Date:  2005-04       Impact factor: 9.461

10.  Intraperitoneal fat and insulin resistance in obese adolescents.

Authors: 
Journal:  Obesity (Silver Spring)       Date:  2009-08-27       Impact factor: 5.002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.